Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
138 Leser
Artikel bewerten:
(0)

Olainfarm: Olainfarm to Strengthen Belarus Operations

NPK Biotest, a Belarus based producer of medical herbal infusions owned by AS
Olainfarm received a Good Manufacturing Practice certificate of Belarus.  This
will allow starting packing five Olainfarm products for Belarus market within
this year.  In addition, this year NPK Biotest becomes distributor of products
of Tonus Elast in Belarus. 

Olaine, 2018-02-13 09:00 CET (GLOBE NEWSWIRE) --
"Since acquisition of daughter companies we are putting a lot of effort to
integrate them and use as many synergies as we can. In NPK Biotest, we have
created a certified production platform, which will help us use the advantages
provided to local producers in Belarus.  Other European producers also
expressed their interest in using services of NPK Biotest for packing of their
products. 

We also very highly value a long and successful experience that NPK Biotest has
in cooperating with pharmacies and other retailers of Belarus, therefore we
entrusted them with distributing products of Tonus Elast.  We expect that
potential of NPK Biotest will contribute to increasing sales of Tonus Elast in
Belarus", says Olegs Grigorjevs, Chairman of the Board of AS Olainfarm. 

AS Olainfarm acquired Belarus based producer of medical herbal infusions in
2016 in order not only to gain the production platform in Belarus, but also to
add new products to the portfolio of the group.  NPK Biotest is one of the
first private pharmaceutical companies in Belarus.  It was establishes in 1990
in Hrodna by the team of scientists of Belarus Academy of Sciences.  NPK
Biotest develops and produces natural herbal remedies and food supplements. 
Its portfolio contains more than 100 herbal infusions, and mixtures. NPK
Biotest also owns four pharmacies in Hrodna. 

According to preliminary unconsolidated results, sales of AS Olainfarm in 2017
was 91.97 million euros, which is comparable to the sales made in 2016.  Its
sales in Belarus reached 8.76 million euros, making Belarus the fourth biggest
market with a share of almost 10% in total sales. Sales to Belarus in 2017
increased by 20% compared to sales made to this country in 2016.  According to
preliminary results, Sales of NPK Biotest in 2017 reached 2 million euros. 

                                        

 JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45
years of experience in production of medication and chemical and pharmaceutical
products. A basic principle of company's operations is to produce reliable and
effective top quality products for Latvia and the rest of the world. Products
made by the Group are being exported to more than 35 countries of the world,
including the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia. 

         Information prepared by:
         
         Salvis Lapins
         JSC Olainfarm
         Member of the Management Board
         Rupnicu iela 5, Olaine, Latvia, LV 2114
         Phone: +371 6 7013 717
         Fax: +371 6 7013 777
         E-mail: Salvis.Lapins@olainfarm.lv
Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2018 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.